Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial
Open accessThe DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Efficacy and safety of the glucagon-like peptide 1 (GLP-1) analog oral semaglutide and the sodium–glucose cotransporter 2 inhibitor empagliflozin were compared in patients with type 2 diabetes uncontrolled on metformin. RESEARCH DESIGN AND METHODS: Patients were randomized to once-daily open-label treatment with oral semaglutide 14 mg (n = 412) or empagliflozin 25 mg (n = 410) in a 52-week trial. Key end points were change from baseline to week 26 in HbA1c (primary) and body weight (confirmatory secondary). Two estimands addressed efficacy-related questions: treatment policy (regardless of trial product discontinuation or rescue medication) and trial product (on trial product without rescue medication) in all randomized patients. RESULTS: Four hundred (97.1%) patients in the oral semaglutide group and 387 (94.4%) in the empagliflozin group completed the trial. Oral semaglutide provided superior reductions in HbA1c versus empagliflozin at week 26 (treatment policy –1.3% vs. –0.9% [–14 vs. –9 mmol/mol], estimated treatment difference [ETD] –0.4% [95% CI –0.6, –0.3] [–5 mmol/mol (–6, –3)]; P < 0.0001). The treatment difference in HbA1c significantly favored oral semaglutide at week 26 for the trial product estimand (–1.4% vs. –0.9% [–15 vs. –9 mmol/mol], ETD –0.5% [95% CI –0.7, –0.4] [–6 mmol/mol (–7, –5)]; P < 0.0001) and at week 52 for both estimands (P < 0.0001). Superior weight loss was not confirmed at week 26 (treatment policy), but oral semaglutide was significantly better than empagliflozin at week 52 (trial product −4.7 vs. −3.8 kg; P = 0.0114). Gastrointestinal adverse events were more common with oral semaglutide. CONCLUSIONS: Oral semaglutide was superior to empagliflozin in reducing HbA1c but not body weight at 26 weeks in patients with type 2 diabetes uncontrolled on metformin. At week 52, HbA1c and body weight (trial product estimand) were significantly reduced versus empagliflozin. Oral semaglutide was well tolerated within the established safety profile of GLP-1 receptor agonists.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“in the randomised, open-label, multinational 52-week PIONEER 2 trial, oral semaglutide 14 mg resulted in a significantly greater reduction in CRP compared with empagliflozin 25 mg.23”
In the citing paper
“Study designs for these double-blind, randomized controlled trials have been published previously [18–21].”
From Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials (2022) · cites this paper as [20]
In the citing paper
“In PIONEER 2, oral semaglutide reduced CRP by 30%, whereas empagliflozin had no effect despite similar approximately 4% weight loss (24).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [24]
In the citing paper
“In the PIONEER program, four thyroid malignancies occurred in semaglutide-treated patients, versus one in the comparator group”
From Safety of Semaglutide (2021) · cites this paper as [15]
In the citing paper
“The ‘PIONEER’ series of trials [21–30] demonstrated that oral semaglutide has a positive impact on average HbA1c levels and weight reduction compared with several other drug classes (SGLT-2 inhibitor, DPP-4 inhibitor, another GLP-1RA, insulin and placebo).”
From GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art (2022) · cites this paper as [22]
Citations
Cites
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,265
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationStatistical Analysis With Missing Data
Ghosh, S. (1988) · Technometrics · doi:10.1080/00401706.1988.10488446 · Cited by 4,576
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
Self-citationSeaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 2×
“†An episode that is severe, according to theADAclassification (requires assistanceof anotherperson to actively administer carbohydrate, glucagon, or other corrective action) (29).”
BackgroundUser’s manual for the SF-12v2 health survey
Ware, J., Kosinski, M., Bowker, D., Gandek, B., Ware, J. E., & Turner‐Bowker, D. M. (2002) · Cited by 1,085
Pratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790
Self-citationSorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745
Cited by
Items 101–200 of 482
Hauge, C., Breitschaft, A., Hartoft‐Nielsen, M., Jensen, S., & Bækdal, T. A. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1955856 · Cited by 41
Arredouani, A. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108824 · Cited by 36
Hui, E. K., Mukadam, N., Kohl, G., & Livingston, G. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251319054 · Cited by 39
Skriver, C., Friis, S., Knudsen, L. B., Catarig, A., Clark, A. J., Dehlendorff, C., & Mørch, L. S. (2023) · Diabetologia · doi:10.1007/s00125-023-05972-x · Cited by 38
Anam, M., Maharjan, S., Amjad, Z., Abaza, A., Vasavada, A. M., Sadhu, A., Valencia, C., Fatima, H., & Nwankwo, I. (2022) · Cureus · doi:10.7759/cureus.32610 · Cited by 35
Li, W., Chen, X., Xie, X., Xu, M., Xu, L., Liu, P., & Luo, B. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001197 · Cited by 35
“Nauck et al, 2016 NCT00849017 30/50 Matching placebo 52 200 (92/108) 101 (43/58) 301 (45) C”
InfluentialTseng, P., Zeng, B., Hsu, C.-W., Hung, C., Carvalho, A. F., Stubbs, B., Chen, Y., Chen, T., Lei, W., Chen, J.-J., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04018-w · Cited by 36
Barrea, L., Pugliese, G., Muscogiuri, G., Laudisio, D., Colao, A. A. L., & Savastano, S. (2020) · Minerva Endocrinology · doi:10.23736/s0391-1977.20.03179-x · Cited by 38
SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials
Shi, N., Shi, Y., Xu, J., Si, Y.-X., Yang, T., Zhang, M., Ng, D. M., Li, X., & Xie, F. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.668368 · Cited by 39
Advances in GLP-1 treatment: focus on oral semaglutide
Eliaschewitz, F. G., & Canani, L. H. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00713-9 · Cited by 34
“Furthermore, when asked about craving control and craving for savory, patients also reported better feeling with oral semaglutide than empagliflozin [40].”
BackgroundMethodSelf-citationClinical potential of treatment with semaglutide in type 2 diabetes patients
Røder, M. E. (2019) · Drugs in Context · doi:10.7573/dic.212585 · Cited by 37
Kawaguchi, T., Fujishima, Y., Wakasugi, D., Io, F., Sato, Y. A., Uchida, S., & Kitajima, Y. (2024) · Journal of Gastroenterology · doi:10.1007/s00535-024-02158-z · Cited by 34
Chronic kidney disease as a cardiovascular risk factor
Carmena, R., Ascaso, J. F., & Redón, J. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002506 · Cited by 39
Allocca, S., Monda, A., Messina, A., Casillo, M., Sapuppo, W., Monda, V., Polito, R., Maio, G. D., Monda, M., & Marra, M. L. (2025) · Healthcare · doi:10.3390/healthcare13121437 · Cited by 37
Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma?
Mouhammad, Z. A., Vohra, R., Horwitz, A., Thein, A., Andreasen, J. R., Cvenkel, B., Williams, P. A., Azuara‐Blanco, A., & Kolko, M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.824054 · Cited by 35
Ding, Y., Shi, Y., Guan, R., Yan, S., Liu, H., Wang, Z., Li, J., Wang, T., Cai, W., & Ma, G. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2023.107031 · Cited by 31
Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential
AL-Noshokaty, T. M., Abdelhamid, R., Abdelmaksoud, N. M., Khaled, A., Hossam, M., Ahmed, R., Saber, T., Khaled, S., Elshaer, S. S., & Abulsoud, A. I. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.101895 · Cited by 30
Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges
Zhou, Z., Yi, L., Popławska-Domaszewicz, K., Chaudhuri, К. R., Jankovic, J. J., & Tan, E. K. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107770 · Cited by 35
Lingvay, I., Capehorn, M., Catarig, A., Johansen, P., Lawson, J., Sandberg, A., Shaw, R., & Paine, A. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa577 · Cited by 31
Self-citationTilinca, M. C., Tiucă, R. A., Niculas, C., Varga, A., & Ţilea, I. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10601 · Cited by 32
Semaglutide Has Beneficial Effects on Non-Alcoholic Steatohepatitis in Ldlr-/-.Leiden Mice
Inia, J. A., Stokman, G., Morrison, M. C., Worms, N., Verschuren, L., Caspers, M. P. M., Menke, A. L., Petitjean, L., Chen, L., Petitjean, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108494 · Cited by 33
Jain, A., Reichert, S. M., Amadid, H., Braae, U. C., Bradley, R. M., Kim, J. W., Soo, V., & Yale, J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15493 · Cited by 31
Ramos, M., Cummings, M. H., Ustyugova, A., Raza, S. I., de Silva, S. U., & Lamotte, M. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00883-1 · Cited by 29
Management of type 2 diabetes with oral semaglutide: Practical guidance for pharmacists
Kane, M. P., Triplitt, C. L., & Solis‐Herrera, C. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa413 · Cited by 41
Candido, R., Gaiotti, S., Giudici, F., Toffoli, B., Luca, F. D., Velardi, V., Petrucco, A., Gottardi, C., Manca, E., Buda, I., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12186052 · Cited by 29
Wu, W., Tong, H.-M., Li, Y., & Cui, J. (2023) · Endocrine · doi:10.1007/s12020-023-03636-9 · Cited by 30
Małyszczak, A., Przeździecka-Dołyk, J., Szydełko-Paśko, U., & Misiuk‐Hojło, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061797 · Cited by 30
Jordy, A. B., Albayaty, M., Breitschaft, A., Anderson, T. W., Christiansen, E., Houshmand-Øregaard, A., Manigandan, E., & Bækdal, T. A. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00976-x · Cited by 27
Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome
MacIsaac, R. J. (2025) · Future Cardiology · doi:10.1080/14796678.2025.2511412 · Cited by 30
Ren, X., Hua, H., Wu, Y., Zhang, W., Long, X., Bai, Y., & Cheng, N. (2025) · Scientific Reports · doi:10.1038/s41598-025-09807-0 · Cited by 38
Fadini, G. P., Bonora, B. M., Ghiani, M., Anichini, R., Melchionda, E., Fattor, B., Fazion, S., Meregalli, G., Giaccari, A., Avogaro, A., et al. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15554 · Cited by 27
Marassi, M., & Fadini, G. P. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2024.11.005 · Cited by 27
Effects of GLP-1 Agonists on mortality and arrhythmias in patients with Type II diabetes
Al‐Sadawi, M., Aslam, F. M., Tao, M., Alsaiqali, M., Almasry, I. O., Fan, R., Rashba, E. J., & Singh, A. (2023) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2023.101218 · Cited by 34
Ji, L., Agesen, R. M., Bain, S. C., Fu, F., Gabery, S., Geng, J., Li, Y., Lu, Y., Luo, B., Pang, W., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06133-4 · Cited by 27
Hunt, B., Hansen, B. B., Ericsson, Å., Kallenbach, K., Ali, S. N., Dang‐Tan, T., Malkin, S. J. P., & Valentine, W. J. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01125-y · Cited by 28
Liu, Y., He, L., Han, S., Ping, F., Li, W., Xu, L., Zhang, H., & Li, Y. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.039446 · Cited by 27
Mechanism of Semaglutide in MASLD Treatment: Where Is the Master Key?
Ezhilarasan, D. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.17037 · Cited by 28
Optimizing Therapeutic Outcomes With Oral Semaglutide: A Patient-Centered Approach
Isaacs, D. M., Kruger, D. F., & Spollett, G. R. (2020) · Diabetes Spectrum · doi:10.2337/ds20-0016 · Cited by 26
Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how?
Brunton, S., Mosenzon, O., & Wright, E. E. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1798162 · Cited by 29
Guzauskas, G. F., Rind, D. M., Fazioli, K., Chapman, R. H., Pearson, S. D., & Hansen, R. N. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.27.4.455 · Cited by 31
Dong, Y., Chang, C., Lin, J., Yang, W., Wu, L., & Toh, S. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14741 · Cited by 26
SGLT2 Inhibitors: The Next Blockbuster Multifaceted Drug?
Chan, J. C. H., & Chan, M. C. Y. (2023) · Medicina · doi:10.3390/medicina59020388 · Cited by 28
Use of Dulaglutide, Semaglutide, and Tirzepatide in Diabetes and Weight Management
Powell, J., & Taylor, J. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.12.014 · Cited by 27
Cherney, D. Z. I., Belmar, N., Bjornstad, P., Chacko, M. M., Gunnarsson, T. P., Hodgin, J. B., Kretzler, M., Pruijm, M. T., Schytz, P. A., & Tuttle, K. R. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf114 · Cited by 26
Davies, M. J., Bianchi, C., & Del Prato, S. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154242 · Cited by 23
Effects of Semaglutide and Empagliflozin on Inflammatory Markers in Patients with Type 2 Diabetes
Reppo, I., Jakobson, M., & Volke, V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065714 · Cited by 24
van Houtum, W. H., Schrömbges, P. P. G., Amadid, H., van Bon, A. C., Braae, U. C., Hoogstraten, C., & Herrings, H. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01588-5 · Cited by 24
Pratley, R. E., Crowley, M. J., Gislum, M., HERTZ, C. L., Jensen, T. B., Khunti, K., Mosenzon, O., & Buse, J. B. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00994-9 · Cited by 27
Weng, J., Zeng, L., Zhang, Y., Qu, S., Wang, X., Li, P., Fu, L., Ma, B., Ye, S., Sun, J., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14389 · Cited by 25
Implementation of ICH E9 (R1): A Few Points Learned During the COVID-19 Pandemic
Qu, Y., & Lipkovich, I. A. (2021) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-021-00297-6 · Cited by 23
New Hypoglycemic Drugs: Combination Drugs and Targets Discovery
Ni, X., Zhang, L., Feng, X., & Tang, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.877797 · Cited by 26
Tsai, P.-C., Chuang, W.-J., Ko, A. M., Chen, J.-S., Chiu, C., Chen, C., & Yeh, Y. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01789-5 · Cited by 26
Bonora, B. M., Russo, G. T., Leonetti, F., Strazzabosco, M., Nollino, L., Aimaretti, G., Giaccari, A., Broglio, F., Consoli, A., Avogaro, A., et al. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02309-2 · Cited by 24
Singh, A. K., Singh, R., Singh, A., & Misra, A. (2024) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2024.103024 · Cited by 22
Salmen, T., Șerbănoiu, L. I., Bica, I.-C., Serafinceanu, C., Muzurović, E. M., Janež, A., Busnatu, Ș., Banach, M., Rizvi, A. A., Rizzo, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119760 · Cited by 24
The Fight Against Obesity Escalates: New Drugs on the Horizon and Metabolic Implications
Tsilingiris, D., Liatis, S., Dalamaga, Μ., & Kokkinos, A. D. (2020) · Current Obesity Reports · doi:10.1007/s13679-020-00378-x · Cited by 22
Zhong, P., Zeng, H., Huang, M., He, G., & Chen, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.695182 · Cited by 27
Pharmacokinetics and Clinical Implications of Oral Semaglutide for Type 2 Diabetes Mellitus
Clements, J. N., Isaacs, D. M., Hartman, R. E., & Gambill, K. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00951-6 · Cited by 22
Buse, J. B., Christensen, H. N., Harty, B. J., Mitchell, J., Soule, B. P., Zacherle, E. W., Cziraky, M. J., & Willey, V. J. (2023) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-003206 · Cited by 21
Catrina, S., Amadid, H., Braae, U. C., Dereke, J., Ekberg, N. R., Klanger, B., & Jansson, S. P. O. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01614-6 · Cited by 22
Bain, E. K., & Bain, S. C. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14487 · Cited by 20
Kurtzhals, P., Kreiner, F. F., & Bindra, R. S. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110881 · Cited by 22
Rudofsky, G., Amadid, H., Braae, U. C., Catrina, S., Kick, A., Mandavya, K., Roslind, K., Saravanan, P., van Houtum, W. H., & Jain, A. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01668-6 · Cited by 22
Empagliflozin and the Risk of Retinopathy in Patients With Type 2 Diabetes
Tesfaye, H., Paik, J. M., Roh, M., Htoo, P. T., Zakoul, H., Schmedt, N., Koeneman, L., Wexler, D. J., & Patorno, E. (2024) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2024.5219 · Cited by 20
Defining estimands using a mix of strategies to handle intercurrent events in clinical trials
Qu, Y., Shurzinske, L., & Sethuraman, S. (2020) · Pharmaceutical Statistics · doi:10.1002/pst.2078 · Cited by 25
Frazer, M., Swift, C., Gronroos, N. N., Sargent, A., Leszko, M., Buysman, E. K., Alvarez, S., Dunn, T. J., Noone, J. M., & Guevarra, M. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02677-w · Cited by 19
Ando, Y., Shigiyama, F., Hirose, T., & Kumashiro, N. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13533 · Cited by 19
Meier, J. J., Granhall, C., Hövelmann, U., Navarria, A., Plum‐Mörschel, L., Ramesh, C. K., Tannapfel, A., & Kapitza, C. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14632 · Cited by 19
Ishii, H., Hansen, B. B., Langer, J., & Horio, H. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00985-w · Cited by 19
Furusawa, S., Nomoto, H., Yokoyama, H., Suzuki, Y., Tsuzuki, A., Takahashi, K., Miya, A., Kameda, H., Cho, K. Y., Takeuchi, J., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15393 · Cited by 19
Chae, Y., Kwon, S., Nam, J. H., Kang, E., Im, J., Kim, H.-J., & Lee, E. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2363838 · Cited by 18
Khan, T. T. S., Sheikh, Z., Maleknia, S. D., Oveissi, F., Fathi, A., Abrams, T., Ong, H. X., & Traini, D. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2387110 · Cited by 21
Kalra, S., Das, S., & Zargar, A. H. (2022) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_522_21 · Cited by 24
Patient preferences for newer oral therapies in type 2 diabetes
Savarese, G., Sharma, A., Pang, C., Wood, R., & Soleymanlou, N. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.09.009 · Cited by 19
Devi, S., Kaur, N., Kumar, M., & Kumar, P. (2023) · Food Chemistry Advances · doi:10.1016/j.focha.2023.100199 · Cited by 19
Malkin, S. J. P., Hunt, B., Huisman, E. L., Grand, T. S., & Chubb, B. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108759 · Cited by 19
Gruzmark, F. S., Beraja, G. E., Jozic, I., & Lev‐Tov, H. A. (2025) · Wound Repair and Regeneration · doi:10.1111/wrr.70085 · Cited by 17
Jia, S., Wang, Z., Han, R., Zhang, Z., Li, Y., Qin, X., Zhao, M., Xiang, R., & Yang, J. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01542-4 · Cited by 18
Kakouri, A., Kanti, G., Kapantais, E., Kokkinos, A. D., Lanaras, L., Farajian, P., Galanakis, C., Georgantopoulos, G., Vlahos, N., Mastorakos, G. P., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14090869 · Cited by 18
Preference for Type 2 Diabetes Therapies in the United States: A Discrete Choice Experiment
Shubrook, J. H., Radin, M. S., Ali, S. N., Chubb, B., DiPietrantonio, K., Collings, H., Wyn, R., & Smith, M. J. A. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02181-7 · Cited by 17
Mosenzon, O., Miller, E. M., & Warren, M. L. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1800286 · Cited by 16
Hung, C., Zeng, B., Hsu, C.-W., Chen, P., Sun, C., Carvalho, A. F., Stubbs, B., Chen, Y., Chen, T., Lei, W., et al. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000003450 · Cited by 20
A Role of Sodium-Glucose Co-Transporter 2 in Cardiorenal Anemia Iron Deficiency Syndrome
Sano, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065983 · Cited by 18
Saravanan, P., Bell, H. K., Braae, U. C., Collins, E., Deinega, A., Dhatariya, K., Machell, A., Trent, A., & Strzelecka, A. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02973-z · Cited by 16
Fiore, V., Carbotta, G., Barraco, S., Falasca, P., Aricò, C. N., & Barucca, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16174 · Cited by 17
Fernando, K., Bain, S. C., Holmes, P., Jones, P. N., & Patel, D. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01116-9 · Cited by 18
Malkin, S. J. P., Carvalho, D. M., Costa, C., Conde, V., & Hunt, B. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00801-4 · Cited by 16
Exploring beyond numeric weight loss: The metabolic effects of semaglutide
Sokary, S., & Bawadi, H. A. (2025) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2025.03.010 · Cited by 19
Ahmad, N., Alruwayyes, A., AlArjani, A., Tawhari, A. M., Aldosri, A., Alahmari, A., & Balaha, M. F. H. (2026) · Medicine · doi:10.1097/md.0000000000047994 · Cited by 18
Sise, M. E., Katz‐Agranov, N., Strohbehn, I. A., Harden, D., Moreno, D. R., Durbin, C. G., Toribio, M. P., Neilan, T. G., & Zanni, M. V. (2023) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000003227 · Cited by 16
A Bioequivalence Study of Two Formulations of Oral Semaglutide in Healthy Participants
Nielsen, M. S., Brøndsted, L., Kankam, M. K., Morelli, G., Nguyen, D., Skjøth, T. V., Patted, U. R. H., & van Hout, M. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01674-8 · Cited by 15
Forst, T. M., Block, C. E. M. D., Prato, S. D., Frías, J. P., Lautenbach, A., Ludvik, B. H., Marinez, M., Mathieu, C., Müller, T. D., & Schnell, O. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16247 · Cited by 15
Practical guidance for use of oral semaglutide in primary care: a narrative review
Morales, J., Shubrook, J. H., & Skolnik, N. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1788340 · Cited by 14
The cost–effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark
Ehlers, L. H., Lamotte, M., Ramos, M., Sandgaard, S., Holmgaard, P., Frary, E. C., & Ejskjær, N. (2021) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2021-0169 · Cited by 15
Kobayashi, K., Toyoda, M., Hatori, N., Sakai, H., Furuki, T., Chin, K., Kimura, M., Saito, N., Kanaoka, T., Aoyama, T., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109231 · Cited by 16
Tornyos, D., Meuer, M., Lukács, R., Abdallaoui, O. E. A. E., Kupó, P., Faludi, R., & Komócsi, A. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1041200 · Cited by 15
Patoulias, D., Katsimardou, A., Kalogirou, M., Zografou, I., Toumpourleka, M., Imprialos, K. P., Stavropoulos, K., Stergiou, I., Papadopoulos, C. E., & Doumas, M. N. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.04.001 · Cited by 15
Oral GLP1 Analog: Where Does the Tide Go?
Gardner, H. M., & Hamdy, O. (2020) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/1179551420984130 · Cited by 15
Will oral semaglutide be a game-changer in the management of type 2 diabetes in primary care?
Seidu, S., Mellbin, L., Kaiser, M., & Khunti, K. (2020) · Primary care diabetes · doi:10.1016/j.pcd.2020.07.011 · Cited by 14
Li, W. (2021) · Journal of Computational Biophysics and Chemistry · doi:10.1142/s2737416521500289 · Cited by 16
Metadata
- Authors
- Rodbard, H. W., Rosenstock, J., Canani, L. H., Deerochanawong, C., Gumprecht, J., Lindberg, S. Ø., Lingvay, I., Søndergaard, A. L., Treppendahl, M. B., Montanya, E., PIONEER 2 Investigators, Cruz, P., Loredo, L. D., Luquez, C., Moisello, M., Augusto, G. A., Castro, M., Canani, L., Akrap, B., Bulum, T., Rahelic, D., Sunic-Grcic, I., Tusek, S., Avramidis, I., Benroubi, M., Didangelos, T., Karousos, G., Pagkalos, E., Sampanis, C., Somali, M., Domboróczki, Z., Faludi, P., Gaál, Z., Kis-Gombos, P., Kocsis, G., Marton, Z., Sudár, Z., Buscemi, S., Di Carlo, A., Dotta, F., Gambineri, A., Lauro, D., Maranghi, M., Arciszewska, M., Gumprecht, J., Matuszewska, K., Skokowska, E., Stasinska, T., Feofanova, S., Filippova, E., Galstyan, G., Gaysina, L., Kunitsyna, M., Suplotova, L., Antic, S., Djukic, A., Mitrovic, M., Pesic, M., Stokic, E., Jodar, E., Martínez, E., Raya, P. M., Montanya, E., Portillo, C. M., Vera, M. P., Fernández, M. R., San Jose, P., Riera, M. T., Boonyavarakul, A., Deerochanawong, C., Sriwijitkamol, A., Ajani, D., Armas, E., Barbel-Johnson, K., Bartilucci, D., Bonabi, G., Busch, R., Butuk, D., Cannon, K., Chase, C., Chaykin, L., Cheekati, V., Davis, T., Delgado, B., Farris, N., Graves, M., Ha, C., Harper, L., Herring, S., Hewitt, M., Hsia, D., Jackson, R., Jardula, M., Joyce, M., Juarez, M., Kapoor, A., Karounos, D., Kayne, D., Lacour, A., Ledesma, G., Lingvay, I., Lipetz, R., Lomboy, J., Lynd, S., Morawski, E., Morin, R., Murphy, R., Overcash, J. S., Pullman, J., Rodbard, H. W., Rosenstock, J., Ruoff, G., Steenkamp, D., Toro, H., Trachtenbarg, D., Tulloch, B., Weisbrot, A., & Wright, A.
- Affiliations
- Endocrine Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
- Novo Nordisk (Denmark) (DK)
- ORCID
- Lindberg, Søren Østergaard
- Augusto, Gustavo Akerman
- Bulum, Tomislav
- Avramidis, Iakovos
- Didangelos, Triantafyllos
- Buscemi, Silvio
- Dotta, Francesco
- Gambineri, Alessandra
- Lauro, Davide
- Maranghi, Marianna
- Galstyan, Gagik
- Boonyavarakul, Apussanee
- Sriwijitkamol, Apiradee
- Busch, Robert
- Herring, Sharon
- Hsia, Daniel
- Overcash, J. Scott
- Steenkamp, Devin
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-10-07
- Volume
- 42
- Issue
- 12
- Pages
- 2272-2281
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2974621372
- Cited by
- 463
- References
- 37
- Citations by year
- 2026: 53 · 2025: 85 · 2024: 78 · 2023: 55 · 2022: 64 · 2021: 59 · 2020: 60 · 2019: 8
- FWCI
- 38.76
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Use Siena air (University of Siena) (submittedVersion)
- Lume (Universidade Federal do Rio Grande do Sul) (submittedVersion, cc-by-nc-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- oral semaglutide, empagliflozin, type 2 diabetes, metformin failure, GLP-1 receptor agonists, SGLT2 inhibitors, glycemic control, HbA1c, weight loss, gastrointestinal adverse effects, drug safety, treatment policy estimand
- MeSH terms
- Semaglutide, Administration, Oral, Adult, Benzhydryl Compounds, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Glucagon-Like Peptides, Female, Glucosides, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Weight Loss, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.